Novel Drugs Recently Authorized by EMA and FDA (Q4, 2022)
نویسندگان
چکیده
EMA (EUROPEAN MEDICINES AGENCY): (A) TRACTO ALIMENTARIO Y METABOLISMO: Fosdenopterina (Nulibry®): deficiencia de cofactor molibdeno. Maralixibat (Livtencity®): prurito colestático.(H) PREPARACIONES HORMONALES SISTÉMICAS: Abaloparatida (Eladynos®): osteoporosis. (J) ANTIINFECCIOSOS SISTÉMICOS: Nirsevimab (Beyfortus®): virus respiratorio sincitial. Vacuna COVID-19 recombinante (VidPrevtyn Beta®): covid-19. DENGUE Tetravalente (Qdenga®): dengue. Maribavir citomegalovirus. (L) AGENTES ANTINEOPLÁSICOS E INMUNOMODULADORES: Voclosporina (Lupkynis®): nefritis lúpica. Tabelecleucel (Ebvallo®): enfermedad linfoproliferativa postrasplante. Sutimlimab (Enjaymo®): anemia hemolítica por crioaglutininas. (R) SISTEMA RESPIRATORIO: Tezepelumab (Tezspire®): asma. (V) VARIOS: Gozetotida (Locametz®): diagnóstico del cáncer próstata. FDA (U.S. FOOD & DRUG ADMINISTRATION): Teplizumab (Tzield®): diabetes mellitus tipo 1. Microbiota fecal viva (Rebyota®): profilaxis la recurrencia Clostridioides difficile. (B) SANGRE HEMATOPOYÉTICO: Etranacogene dezaparvovec (Hemgenix®): hemofilia. Betibeglogene autotemcel (Zynteglo®): talasemia beta. Nadofaragene Firadenovec (Adstiladrin®): vejiga. Tremelimumab (Imjudo®): hepatocelular. Mirvetuximab soravtansina (Elahere®): ovario. Olutasidenib (Rezlidhia®): leucemia mieloide aguda. Adagrasib (Krazati®): pulmón. Futibatinib (Lytgobi®): colangiocarcinoma intrahepático. (N) NERVIOSO: Taurursodiol/Fenilbutirato (Relyvrio®): esclerosis lateral amiotrófica (ELA). Elivaldogene (Skysona®): adrenoleucodistrofia cerebral. Ublituximab (Briumvi®): múltiple. (P) (S) ÓRGANOS SENSORIALES: Omidenepag isopropilo (Omlonti®): glaucoma. Tiosulfato sódico (Pedmark®): antídoto cisplatino. Gadopiclenol (Elucirem®): imagen RMN. Xenón [Xe-129] hiperpolarizado (Xenoview®):
منابع مشابه
Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
n engl j med 370;9 nejm.org february 27, 2014 794 likely that such efficacy will be shown until the vaccines are licensed and postmarketing surveillance commences. Recent evidence suggests that EV71 vaccines do not provide cross-protection against all circulating genetic lineages of EV71 or against coxsackievirus A16.5 Thus, the Chinese C4A-based vaccines may not generate protective immunity ag...
متن کاملPostmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
OBJECTIVES To characterise postmarketing studies for drugs that were newly approved by the US Food and Drug Administration and the European Medicines Agency. DESIGN AND SETTING Cross-sectional analysis of postmarketing studies registered in ClinicalTrials.gov until September 2014 for all novel drugs approved by both regulators between 2005 and 2010. Regulatory documents from both agencies wer...
متن کاملMolecular docking study of anti-viral FDA-approved drugs as novel entry and replication Ebola viral inhibitors
Background & Objective: Because of the reported high ability of virulence and the lack of appropriate drug of Ebola virus during the last decades, many investigations have been accomplished regarding discovery and the introduction of anti-Ebola drugs. The aim of this research was the bioinformatical study of entry and replication of Ebola viral inhibition by drug repurposing. Materials & Method...
متن کاملA Q4/Q4 continuum structural topology optimization implementation
A node-based design variable implementation for continuum structural topology optimization in a finite element framework is presented and its properties are explored in the context of solving a number of different design examples. Since the implementation ensures Ccontinuity of design variables, it is immune to elementwise checkerboarding instabilities that are a concern with element-based desi...
متن کاملWhen EMA and FDA decisions conflict: differences in patients or in regulation?
Are Americans more resistant to the risks and more likely to benefit from certain drugs than Europeans or, on the contrary, is the European Medicines Agency (EMA) more resistant than the US Food and Drug Administration (FDA) to the drug industry’s desire to get approval for drugs with unique risks but without compensating benefits? This question arises because the FDA has recently approved two ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Anales De La Real Academia Nacional De Farmacia
سال: 2022
ISSN: ['1697-4271', '1697-428X', '2174-8756']
DOI: https://doi.org/10.53519/analesranf.2022.88.04.07